Category Archives: Human Longevity

Combining the directorial skills of Simon Stone, the screenplay adaptation by Moira Buffini and the cinematography of Mike Eley, The Dig portrays a dynamic, true story intertwining themes of history and modern existential longing with dramatic scenes concerning life, death, love and family.

The Netflix film, released Jan. 29, is an adaptation of John Prestons 2007 novel of the same name and is based on a true story. Taking place in the rustic countryside of Suffolk, England on the eve of World War II, self-taught archaeologist Basil Brown, played by Ralph Fiennes, embarks on a dig to uncover whats believed to be ancient Anglo-Saxon ruins potentially dating as far back as the Vikings or further.

The site lies on the vast estate owned by Edith Pretty, played by 2013s The Great Gatsby star Carey Mulligan. Pretty is a widow left with one son and a dream to dig up three large, grassy, hill-like mounds located in the fields. Though the archaeologist is unconvinced theres anything significant to be found, attempted grave robberies have convinced Pretty theres something extremely valuable hidden within.

Brown, a local archaeologist with the Ipswich Museum, leads the Sutton Hoo excavation, with Peggy Piggott, played by Lily James. Hes portrayed as a modest working man with vast knowledge of the land. His soil expertise is what leads Pretty to hire him in the first place.

Given the politics of the time period, the dig site is seen as an area of national interest as Britain was preparing to protect the countrys ancient ruins from German air raids.

The story shifts toward a more intimate focus, concerned with family and belonging, when Prettys young son Robert, played by Archie Barnes, grows increasingly fond of Brown. The two are portrayed almost as father and son, bringing the narrative closer to one of community rather than national glory.

The Dig captures a unique perspective of existentialism, with the story taking place during Britains mobilization before wartime. It keeps audiences reflecting on the significance of human legacy, wondering what will be left of us after we are gone.

As the characters on screen are forced to come to terms with their own mortality in an age of destruction and uncertainty, we get a better understanding of the significance of these ancient runes that are still standing a testament of humanitys longevity.

Aside from matters of historical and ancestral significance, The Dig is a nod to the struggles that affect ordinary people of today, with overtones of love, lust and heartbreak.

What keeps viewers satisfied throughout the film is the unchanging and breathtaking scenery of the Suffolk countryside. Eley yields cinematographic mastery by capturing the lush wheat fields of eastern England, combined with enticing pan shots of the site to emphasize how massive this project is, yet also how seemingly small of a role it plays in the full history of the nation.

Stone keeps audiences holding their breaths by turning a story of national history into a heartfelt drama that so accurately touches on struggles that afflict people of all backgrounds.

Its worth mentioning the film has received some criticism for sexist portrayal of characters, for ageism despite the whimsical setting and for fictionalizing some of the truth.

Be that as it may, it was worth the watch.

At surface level, The Dig seems like a story of historical drama, but it takes audiences into deep-cutting, emotionally luring instances of love, loss, triumph and human connection.

Read the original:
REVIEW: 'The Dig' is captivating, beautiful exploration of past The Daily Free Press - Daily Free Press

So how do you build a brand in the quick serve restaurant industry? Sure, you need a good product, and it has to be delivered efficiently.

But its that word of mouth, organic growth that may what cements your place in the industry, one that took a punch to the gut in 2020 from the coronavirus pandemic.

Thats been a key for BJ Crist and Gus Rezende with Social Entertainment, owners of the local Tropical Smoothie Caf franchises. Last month marked 11 years since Crist and Claire Foret opened the first location in Lafayette in the Oil Center, and he and Rezende have since opened four more across Acadiana.

Now they are starting another round of expansion with five more planned for south Louisiana. They will open a location on Johnston Street near E Broussard Road possibly in the fall and are looking to open in the Broussard/Youngsville area, the Scott area, the Lake Charles area and the Houma/Thibodaux area, Crist said.

Weve spent the time and effort to build the brand over 11 years, Crist said. Word of mouth is key to anything. Its what really drives longevity. Its not entirely the thing that will be the quick success story, but word of mouth is what builds a brand. Thats what weve been trying to do in trying to saturate the Acadiana area.

The expansion comes as Tropical Smoothie has emerged as one of the hotter brands in the country. Entrepreneur Magazine ranked Tropical Smoothie Caf 18th in its top 500 franchises for 2021, and last month the company reported its ninth straight year of same-store sales growth despite the turmoil many restaurants experienced when the pandemic severely limited what restaurants could do.

Tropical Smoothie Caf opened 99 new locations last year, including its 900th that opened in Georgia. It also has 254 new franchise agreements, 70% of which came from existing franchisees, and expects to open 1,000 new locations this year.

CEO Charles Watson credited the franchisees and crews for the growth despite the odds.

I'm incredibly proud of how this brand thrived during difficult circumstances and times, Watson said. Our focus on serving our guests drove us to develop new and exciting menu items and create multiple delivery methods for guests to experience all we have to offer all while heightening our dedication to safety and our commitment to the communities we serve.

The company has developed a model thats become popular by offering fruit smoothies and lighter, healthier menu items with an emphasis on customer experience, but it was the response to the pandemic that may have been the difference.

It shifted quickly at the start of the pandemic, adjusting quickly to offer curbside and delivery options and relaunching its mobile app, according to a report in QSR Magazine. It also offered franchisees 50% royalty relief for eight weeks and helped them secure PPP funding and negotiate rent relief.

The growth continued last year despite the obstacles, said Crist, who was named Multi-Unit Franchisee of the Year in August.

Its grown quite substantially in the last decade, he said. I feel like were really kind of catching our wind and the recognition. A little over a year ago they opened up on in Baton Rouge. It took a little while, but within six months it was doing some great numbers. When youre going into a new market that has no brand awareness, it usually takes a little time.

A big key, he noted, has been the customer experience. Much like Chick-Fil-A and emphasis on customer service, employees have high expectations for how they treat the customer.

Each location employs up to 25 people, many of which have gone through a screening process, Crist said. They look for employees with personality, who can hold a conversation with the customer and possibly change their day a little bit with just a little human interaction.

In turn, the company offers frequent pay raises to build continuity.

We really have high expectations on how we treat people from a hospitality standpoint, Crist said. We try to instill hospitality in the kids who work for us. I think what truly drives the success is the experience, the human factor and making people feel like, Thats my spot. Thats where I go.

Continue reading here:
Tropical Smoothie Cafe to open five more locations, including three in Acadiana - The Advocate

Thanos Tzempelikos, professor in the Lyles School of Civil Engineering, has received the prestigious Leon Gaster Award from the Society of Light and Lighting as a co-author of the paper "Cross-validation and Robustness of Daylight Glare Metrics." This award is presented annually, naming the best paper of the year concerned with lighting applications. The award was presented at the societys Annual Awards evening in December in London.

Dr. David Waters is the recipient of the Center on Aging and the Life Course's (CALC) Outstanding Professor Award.Waters is professor emeritus in the College of Veterinary Medicine and a CALC faculty associate. Waters teaches biology of aging and received numerous student nominations for the award, which recognizesexceptional teaching and mentoring of emerging scholars in aging. He is director of the Center for Exceptional Longevity Studies at the Gerald P. Murphy Cancer Foundation.

* * * * *

Orr Fellowship, a postgraduate professional development program based in Indianapolis, has recently selected four Purdue seniors as Orr fellows. The Orr Fellowship is one of Indianas most celebrated nonprofit talent programs. The students Miguel Diaz, Sean ODell, Eleanor Hamilton and Hannah Vanderbosch were chosen out of nearly 1,300 applicants and will begin at one of 46 Orr Fellowship partner companies upon graduating in May. They also will participate in Orr Fellowship programming dedicated to nurturing entrepreneurship and developing strong leadership skills.

Christine McCall, a graduate research and teaching assistant in the College of Health and Human Sciences, earned a top honor from the National Council on Family Relations for a paper. McCall won the Outstanding Student and New Professional Paper Award for her paper titled A Part of Our Family? Effects of Psychiatric Service Dogs on Quality of Life and Relationship Functioning in Military-Connected Couples.

See more here:
Appointments, honors and activities - Purdue News Service

DAVIS, Calif., Feb. 8, 2021 /PRNewswire/ --Evolve BioSystems announced today that it completed a substantial first close in a $55 million Series D round of funding, led by Cargill, the global food, agricultural, financial and industrial products company and Manna Tree, an investment firm committed to improving human health. The new capital will be used to help the companycontinue commercializing a next generation of probiotic capable of addressing a widespread deficiency in the infant gut microbiome.

"We are thrilled to announce our newest investors as we continue our quest to address this health crisis in newborns," said Timothy Brown, CEO of Evolve BioSystems. "Our research found that more than 90 percent of infants in the U.S. are missing the critical bacteria, Bifidobacterium longum subsp. infantis (B. infantis), which is widely documented as a key component of the infant gut microbiome. The financial support announced today, which includes strong continued support from our earlier investors, will help continue our mission to make a healthier future for our children during infancy and beyond."

Evolve BioSystems manufactures Evivo, a proprietary groundbreaking probiotic proven to resolve infant gut dysbiosis, or Newborn Gut Deficiency. Evivo is comprised of activated B. infantis EVC001, which studies have shown guides critical development of infants' digestive and immune systems. Evivo restores this missing bacterium to the infant gut microbiome, reducing potentially pathogenic bacteria by 80 percent as well as significantly reducing intestinal inflammation. These pathogens are linked to higher risk of both short- and long-term health issues including colic, diaper rash, eczema, asthma, allergies and Type 1 Diabetes.

"Evivo, Evolve BioSystem's innovative infant probiotic, has been proven to have a dramatic impact on the developing infant gut, and to guide long-term health trajectory. This round of financing will continue to raise consumer and health care practitioner awareness, while supporting continued research and development. We are proud to partner with innovators like Tim and the entire Evolve team who are at the forefront of food and biotechnology" said Gabrielle "Ellie" Rubenstein, Co-Founder and CEO of Manna Tree. "This important investment is at the very core of our mission at Manna Tree - investing in human health."

The health benefits of Evivo are documented through numerous clinical studies and peer-reviewed publications. The investments of Manna Tree and Cargill come on the heels of the most recent breakthrough in the Evolve research, the U.S. Microbiome Survey, recently published in Scientific Reports. The research shows that nine out of ten U.S. infants are suffering from Newborn Gut Deficiency, increasing risk to early infant health and development. The study is the largest to date to benchmark the widespread levels of potential pathogenic bacteria in U.S. infants and the substantial deficiency B. infantis.

"Evolve BioSystem's Evivo has the potential to be a highly distinctive probiotic for infants and we are delighted to work with them to scale its impact," said Chuck Warta, president of Cargill's health technologies business. "Our goal is to help humans live more healthy days right from the start. Together, we can harness our respective expertise and knowledge in nutrition, digestive and immune health to bring next generation ingredient solutions to our customers."

Through its collaboration with the Bill & Melinda Gates Foundation, Evolve BioSystems is currently involved in a clinical trial at the International Centre for Diarrheal Disease Research in Bangladesh to assess the impact of Evivo on infants who have been diagnosed with severe acute malnutrition.

As part of the investment, Cargill and Manna Tree will serve as lead investors and join the company's board of directors. Other Evolve BioSystems investors in this round include Horizons Ventures, Johnson & Johnson Innovation JJDC, Inc., Spruce Capital Partners, Acre Venture Partners and Bow Capital. Evolve was spun-off from the Foods for Health Institute (FFHI) at the University of California, Davis in 2014.

For more information on Evolve BioSystems and Evivo, visit http://www.evolvebiosystems.com or http://www.evivo.com. To learn more about the Evolve BioSystems investors, visit Manna Tree at http://www.mannatreepartners.comandwww.Cargill.com.

About Evolve BioSystems, Inc

Evolve BioSystems, Inc. is a privately held microbiome company dedicated to researching solutions to establish, restore, and maintain a healthy gut microbiome. Evolve is a portfolio company of Cargill, Manna Tree, the Bill & Melinda Gates Foundation and Horizons Ventures, the venture division of the Li Ka Shing Foundation. Evolve is a spin-off from the Foods for Health Institute (FFHI) at the University of California, Davis and builds on more than a decade of research into understanding the unique partnership of the infant gut microbiome and breast milk components.

About Cargill

Cargill's 155,000 employees across 70 countries work relentlessly to achieve our purpose of nourishing the world in a safe, responsible and sustainable way. Every day, we connect farmers with markets, customers with ingredients, and people and animals with the food they need to thrive.

We combine 155 years of experience with new technologies and insights to serve as a trusted partner for food, agriculture, financial and industrial customers in more than 125 countries. Side-by-side, we are building a stronger, sustainable future for agriculture. For more information, visitCargill.comand ourNews Center.

About Manna Tree

Manna Tree is a Vail, Colorado-based investment firm committed to improving human health through nutrition. The firm invests in and actively partners with growth-stage companies. We believe the future of health, well-being and longevity is attainable through innovation in food. Manna Tree has $235 million in assets under management, as of September 2020, and has made five investments to date: Vital Farms, Verde Farms, MycoTechnology, Nutriati, and Gotham Greens. http://www.mannatreepartners.com.

SOURCE Evolve BioSystems

Read the rest here:
Evolve BioSystems Announces Major Strategic Investment from Cargill and Manna Tree to Support Innovative Probiotic That Dramatically Improves Infant...

NEW YORK, Feb. 8, 2021 /PRNewswire/ -- Kantaro Biosciences, LLC, a joint venture between the Mount Sinai Health System and RenalytixAI (LSE:RENX / NASDAQ: RNLX), and manufacturing partner Bio-Techne Corporation (NASDAQ: TECH), entered into a marketing and distribution agreement with Atrys Health (BME: ATRY), a biomedical company dedicated to providing diagnostic services and medical treatments of excellence. Atrys Health will offer COVID-SeroKlir and COVID-SeroIndex, Kantaro's quantitative SARS-CoV-2 IgG antibody test kits, in select European and South American territories, including Spain, Portugal, Colombia, Brazil, Peru and Chile.

Atrys Health is a distributor for Kantaro quantitative antibody tests in select European and South American territories.

The Kantaro tests have received a CE Mark for detectingthe presence and precise level of neutralizingIgG antibodiesthat areproduced as part of the immune response to COVID-19 virus exposure. The Kantaro testsare also the first and only quantitative antibody tests that do not require proprietary equipment, meaning they can be run easily in anyapproved clinical laboratory.Quantitative testing for neutralizing antibodiescaninform healthcare decision-makingandpublic health policiesworldwide.

"Atrys Health is the latest in a growing list of high-qualitydistributionpartners. This agreement represents another critical step forward in bringing the Kantaro quantitative antibody tests to doctors, patients and researchers in regions affected by COVID-19," said Sara Barrington, Kantaro's chief commercial officer. "We believe this type of antibody testing is increasingly relevant at this point in the pandemic to provide peace of mindand answer important questions about vaccine response, longevityand immunity."

Isabel Lozano, CEOof Atrys Health, said: "Our partnership with Kantaro diversifies and widens our portfolio of diagnostics at the forefront of innovation. We humbly embrace the opportunity to make the Kantaro quantitative antibody testsavailableto our customers in Europe and South America and bepart of the globaleffort to increase testing and begin to recover from the COVID-19 pandemic."

COVID-SeroKlirand COVID-SeroIndexareenzyme-linked immunosorbent assays(ELISA)that havedemonstrated 97.8% sensitivityand 99.6% specificityfor detecting COVID-19 IgG antibodies, making them highly accurate with low potential for false results.The high precision results froma two-step process that utilizes two virus antigens: the receptor-binding domain(RBD)and the full-length spike protein.

Theunderlying technology in theKantaro quantitative antibody test is based on research performed attheIcahn School of Medicine at Mount Sinai in New York City.The Mount Sinai technologyhasalreadybeen used in a highly diverse population of over 86,000 patient samples to screen for convalescent plasma donors anddetermine past infections in the clinical assessment of potentially life-threatening complications from COVID-19, including lung, kidney and cardiovascular disease. This technology has been utilized extensivelyin peer-reviewed research published in ScienceandNature.

About Kantaro Biosciences

Kantaro Biosciences, a joint venture between the Mount Sinai Health System and RenalytixAI plc, is dedicated to ensuring that high-quality diagnostic tests for critical health challenges are accessible. The company provides rigorous, results-driven and reproducible diagnostics to advance the care and well-being of people, communities and society. Kantaro specializes in the rapid scale-up of groundbreaking diagnostic innovations and the creation of partnerships to bring these crucial technologies to market. For more information, visitwww.kantarobio.comand follow Kantaro on Twitter @kantarobio.

About Bio-Techne Corporation

Bio-Techne Corporation (NASDAQ: TECH) is a global life sciences company providing innovative tools and bioactive reagents for the research and clinical diagnostic communities. Bio-Techne products assist scientific investigations into biological processes and the nature and progress of specific diseases. They aid in drug discovery efforts and provide the means for accurate clinical tests and diagnoses. With thousands of products in its portfolio, Bio-Techne generated approximately $739 million in net sales in fiscal 2020 and has over 2,300 employees worldwide. For more information on Bio-Techne and its brands, please visit http://www.bio-techne.com.

About the Mount Sinai Health System

The Mount Sinai Health System is New York City's largest academic medical system, encompassing eight hospitals, a leading medical school, and a vast network of ambulatory practices throughout the greater New York region. Mount Sinai is a national and international source of unrivaled education, translational research and discovery, and collaborative clinical leadership ensuring that we deliver the highest quality carefrom prevention to treatment of the most serious and complex human diseases. The Health System includes more than 7,200 physicians and features a robust and continually expanding network of multispecialty services, including more than 400 ambulatory practice locations throughout the five boroughs of New York City, Westchester, and Long Island. The Mount Sinai Hospital is ranked No. 14 on U.S. News & World Report's "Honor Roll" of the Top 20 Best Hospitals in the country and the Icahn School of Medicine as one of the Top 20 Best Medical Schools in country. Mount Sinai Health System hospitals are consistently ranked regionally by specialty and our physicians are in the top 1% of all physicians nationally by U.S. News & World Report.

For more information, visit https://www.mountsinai.orgor find Mount Sinai on Facebook, Twitterand YouTube.

About Renalytix AI plc

RenalytixAI is a developer of artificial intelligence-enabled clinical in vitro diagnostic solutions for kidney disease, one of the most common and costly chronic medical conditions globally. The Company's products are being designed to make significant improvements in kidney disease diagnosis, transplant management, clinical care, patient stratification for drug clinical trials, and drug target discovery. For more information, visit renalytixai.com.

1 Intended uses of COVID-SeroKlir may vary by country.

View original content to download multimedia:http://www.prnewswire.com/news-releases/kantaro-and-atrys-health-partnership-expand-global-footprint-of-quantitative-covid-19-antibody-tests-in-europe-and-south-america-301223660.html

SOURCE Kantaro Biosciences LLC

Read more:
Kantaro and Atrys Health Partnership Expand Global Footprint of Quantitative COVID-19 Antibody Tests in Europe and South America - BioSpace

Through centuries of evolution, the human body and its surrounding environments have adapted to improve health and promote longevity. For example, the increasing emphasis on hygiene has been effective in combating parasites that cause disease.

These changes have been crucial, as evidenced by the greater life expectancies and lower disease rates in certain regions of the world. However, these benefits come with trade-offs.

Parasites and humans share a long history of coexistence. It is likely that the human immune function developed in relation to parasitic mechanisms.

The old friends hypothesis states that these parasites were like old friends of the human body that helped improve tolerance and function and that their decline led to a higher prevalence of allergic responses and autoimmune conditions.

This decline may also promote inflammaging, which is a chronic form of inflammation that worsens with progressing age. Inflammaging contributes to several age-related conditions, such as dementia, cancer, osteoporosis, and heart disease.

One recent study shows that inflammaging may exacerbate symptoms of COVID-19, as well.

Bruce Zhang and Dr. David Gems, from the Institute of Healthy Ageing at University College London in the United Kingdom, conducted a review of the existing literature to explore the use of parasite worms as a therapy to reverse conditions linked to inflammaging. This review article appears in the journal eLife.

The authors focused their research on a specific group of parasitic worms called helminths, which include roundworms, tapeworms, and flukes. These parasites live inside host organisms, such as human bodies, and take advantage of their immune responses in order to survive.

These findings also provide a glimpse into the intricacies of the human bodys immune functions.

Scientists associate the decline of helminths with multiple inflammatory conditions that occur earlier in life. These include asthma, eczema, multiple sclerosis (MS), rheumatoid arthritis, inflammatory bowel disease, and type 1 diabetes.

Current evidence supports the idea that both natural and deliberate infection with helminths can combat these inflammatory conditions.

Indeed, in 1976, researcher J. A. Turton published a report in which he explained that his hookworm infection reduced the severity of his allergies.

A more recent study which Marc Charabati, of the University of Montreal in Canada, led showed that infecting mice with helminths eased their MS symptoms.

Although these findings suggest that restorative helminth therapy may address pre-aging inflammatory conditions, the question of whether or not it can prevent conditions that occur in older age remains.

A key characteristic of inflammaging is a consistent increase in pro-inflammatory proteins in the blood. Multiple experiments have shown that helminth infection can suppress levels of these pro-inflammatory proteins.

In contrast, administering anthelmintic treatments which can kill helminths increased the inflammatory response of these proteins.

Although the direct administration of helminths can be beneficial, it can also cause undesired infections. A viable alternative is to utilize the molecular components of helminth mechanisms.

One experiment, which Jenny Crowe and others at the University of Glasgow in the U.K. conducted, incorporated this concept in a mouse model that ate a high calorie diet. Specifically, the team administered a protein called ES-62, which is an anti-inflammatory molecule derived from roundworm secretion.

They found that ES-62 prevented both the degradation of the gut barrier and the enlargement of fat tissue, which are mechanisms that contribute to inflammaging.

The mice also showed a 12% increase in their median lifespan. This suggests that ES-62 was able to suppress inflammaging and limit health-related age acceleration.

Similar studies have indicated the effectiveness of helminths and helminth-secreted products in protecting against rheumatoid arthritis, atherosclerosis, and type 2 diabetes.

There is also some evidence that points to helminth therapy in cancer resistance. A few studies in mice have shown that tapeworms prevented the formation of colon tumors.

However, it is important to note that certain helminths can cause cancer, as well. For example, the trematode parasite Schistosoma haematobium can cause bladder cancer.

Although these studies do not confirm that helminths can directly reduce inflammaging, they do show the ability of helminths to protect against the processes that ultimately lead to it.

Zhang and Dr. Gems raise important questions regarding helminth therapy research. These include: What are optimal ages to apply such therapy to reduce inflammaging? Would helminth therapy act only in a preventive fashion (typical of anti-aging treatments), or could it reverse existing disease symptoms?

They also state the necessity of understanding the pathways that shape anti-inflammaging properties.

As Dr. Gems says, In the wake of successes during the last century in eliminating the evils of helminth infections, the time now seems propitious to explore further their possible benefits, particularly for our aging population strange though this may sound.

Read the rest here:
Parasite infections may prevent aging and disease - Medical News Today

Overview for Longevity and Anti-senescence Therapy Market Helps in providing scope and definitions, Key Findings, Growth Drivers, and Various Dynamics.

Longevity and Anti-senescence Therapy Market Data and Acquisition Research Study with Trends and Opportunities 2019-2024The study of Longevity and Anti-senescence Therapy market is a compilation of the market of Longevity and Anti-senescence Therapy broken down into its entirety on the basis of types, application, trends and opportunities, mergers and acquisitions, drivers and restraints, and a global outreach. The detailed study also offers a board interpretation of the Longevity and Anti-senescence Therapy industry from a variety of data points that are collected through reputable and verified sources. Furthermore, the study sheds a lights on a market interpretations on a global scale which is further distributed through distribution channels, generated incomes sources and a marginalized market space where most trade occurs.

Along with a generalized market study, the report also consists of the risks that are often neglected when it comes to the Longevity and Anti-senescence Therapy industry in a comprehensive manner. The study is also divided in an analytical space where the forecast is predicted through a primary and secondary research methodologies along with an in-house model.

Download PDF Sample of Longevity and Anti-senescence Therapy Market report @ https://hongchunresearch.com/request-a-sample/113635

Key players in the global Longevity and Anti-senescence Therapy market covered in Chapter 4:Acorda TherapeuticsUnity BiotechnologyAntoxereneCelgeneCohbarSenex BiotechnologyHuman Longevity Inc.T.A. SciencesAgex TherapeuticsRecursion PharmaceuticalsCalico Life SciencesSpotlight BiosciencePowervision Inc.Sierra Sciences LlcRestorbioInsilico MedicineOisin BiotechnologySenolytic TherapeuticsProteostasis Therapeutics Inc.Prana Biotechnology Ltd.Cleara Biotech

In Chapter 11 and 13.3, on the basis of types, the Longevity and Anti-senescence Therapy market from 2015 to 2026 is primarily split into:Senolytic Drug TherapyGene TherapyImmunotherapyOthers

In Chapter 12 and 13.4, on the basis of applications, the Longevity and Anti-senescence Therapy market from 2015 to 2026 covers:LongevitySenescence InhibitionCardiovascular DiseasesNeural Degenerative DiseasesOphthalmology DisordersCancer

Geographically, the detailed analysis of consumption, revenue, market share and growth rate, historic and forecast (2015-2026) of the following regions are covered in Chapter 5, 6, 7, 8, 9, 10, 13:North America (Covered in Chapter 6 and 13)United StatesCanadaMexicoEurope (Covered in Chapter 7 and 13)GermanyUKFranceItalySpainRussiaOthersAsia-Pacific (Covered in Chapter 8 and 13)ChinaJapanSouth KoreaAustraliaIndiaSoutheast AsiaOthersMiddle East and Africa (Covered in Chapter 9 and 13)Saudi ArabiaUAEEgyptNigeriaSouth AfricaOthersSouth America (Covered in Chapter 10 and 13)BrazilArgentinaColumbiaChileOthersRegional scope can be customized

For a global outreach, the Longevity and Anti-senescence Therapy study also classifies the market into a global distribution where key market demographics are established based on the majority of the market share. The following markets that are often considered for establishing a global outreach are North America, Europe, Asia, and the Rest of the World. Depending on the study, the following markets are often interchanged, added, or excluded as certain markets only adhere to certain products and needs.

Here is a short glance at what the study actually encompasses:Study includes strategic developments, latest product launches, regional growth markers and mergers & acquisitionsRevenue, cost price, capacity & utilizations, import/export rates and market shareForecast predictions are generated from analytical data sources and calculated through a series of in-house processes.

However, based on requirements, this report could be customized for specific regions and countries.

Brief about Longevity and Anti-senescence Therapy Market Report with [emailprotected]https://hongchunresearch.com/report/longevity-and-anti-senescence-therapy-market-size-2020-113635

Some Point of Table of Content:

Chapter One: Report Overview

Chapter Two: Global Market Growth Trends

Chapter Three: Value Chain of Longevity and Anti-senescence Therapy Market

Chapter Four: Players Profiles

Chapter Five: Global Longevity and Anti-senescence Therapy Market Analysis by Regions

Chapter Six: North America Longevity and Anti-senescence Therapy Market Analysis by Countries

Chapter Seven: Europe Longevity and Anti-senescence Therapy Market Analysis by Countries

Chapter Eight: Asia-Pacific Longevity and Anti-senescence Therapy Market Analysis by Countries

Chapter Nine: Middle East and Africa Longevity and Anti-senescence Therapy Market Analysis by Countries

Chapter Ten: South America Longevity and Anti-senescence Therapy Market Analysis by Countries

Chapter Eleven: Global Longevity and Anti-senescence Therapy Market Segment by Types

Chapter Twelve: Global Longevity and Anti-senescence Therapy Market Segment by Applications 12.1 Global Longevity and Anti-senescence Therapy Sales, Revenue and Market Share by Applications (2015-2020) 12.1.1 Global Longevity and Anti-senescence Therapy Sales and Market Share by Applications (2015-2020) 12.1.2 Global Longevity and Anti-senescence Therapy Revenue and Market Share by Applications (2015-2020) 12.2 Longevity Sales, Revenue and Growth Rate (2015-2020) 12.3 Senescence Inhibition Sales, Revenue and Growth Rate (2015-2020) 12.4 Cardiovascular Diseases Sales, Revenue and Growth Rate (2015-2020) 12.5 Neural Degenerative Diseases Sales, Revenue and Growth Rate (2015-2020) 12.6 Ophthalmology Disorders Sales, Revenue and Growth Rate (2015-2020) 12.7 Cancer Sales, Revenue and Growth Rate (2015-2020)

Chapter Thirteen: Longevity and Anti-senescence Therapy Market Forecast by Regions (2020-2026) continued

Check [emailprotected] https://hongchunresearch.com/check-discount/113635

List of tablesList of Tables and Figures Table Global Longevity and Anti-senescence Therapy Market Size Growth Rate by Type (2020-2026) Figure Global Longevity and Anti-senescence Therapy Market Share by Type in 2019 & 2026 Figure Senolytic Drug Therapy Features Figure Gene Therapy Features Figure Immunotherapy Features Figure Others Features Table Global Longevity and Anti-senescence Therapy Market Size Growth by Application (2020-2026) Figure Global Longevity and Anti-senescence Therapy Market Share by Application in 2019 & 2026 Figure Longevity Description Figure Senescence Inhibition Description Figure Cardiovascular Diseases Description Figure Neural Degenerative Diseases Description Figure Ophthalmology Disorders Description Figure Cancer Description Figure Global COVID-19 Status Overview Table Influence of COVID-19 Outbreak on Longevity and Anti-senescence Therapy Industry Development Table SWOT Analysis Figure Porters Five Forces Analysis Figure Global Longevity and Anti-senescence Therapy Market Size and Growth Rate 2015-2026 Table Industry News Table Industry Policies Figure Value Chain Status of Longevity and Anti-senescence Therapy Figure Production Process of Longevity and Anti-senescence Therapy Figure Manufacturing Cost Structure of Longevity and Anti-senescence Therapy Figure Major Company Analysis (by Business Distribution Base, by Product Type) Table Downstream Major Customer Analysis (by Region) Table Acorda Therapeutics Profile Table Acorda Therapeutics Production, Value, Price, Gross Margin 2015-2020 Table Unity Biotechnology Profile Table Unity Biotechnology Production, Value, Price, Gross Margin 2015-2020 Table Antoxerene Profile Table Antoxerene Production, Value, Price, Gross Margin 2015-2020 Table Celgene Profile Table Celgene Production, Value, Price, Gross Margin 2015-2020 Table Cohbar Profile Table Cohbar Production, Value, Price, Gross Margin 2015-2020 Table Senex Biotechnology Profile Table Senex Biotechnology Production, Value, Price, Gross Margin 2015-2020 Table Human Longevity Inc. Profile Table Human Longevity Inc. Production, Value, Price, Gross Margin 2015-2020 Table T.A. Sciences Profile Table T.A. Sciences Production, Value, Price, Gross Margin 2015-2020 Table Agex Therapeutics Profile Table Agex Therapeutics Production, Value, Price, Gross Margin 2015-2020 Table Recursion Pharmaceuticals Profile Table Recursion Pharmaceuticals Production, Value, Price, Gross Margin 2015-2020 Table Calico Life Sciences Profile Table Calico Life Sciences Production, Value, Price, Gross Margin 2015-2020 Table Spotlight Bioscience Profile Table Spotlight Bioscience Production, Value, Price, Gross Margin 2015-2020 Table Powervision Inc. Profile Table Powervision Inc. Production, Value, Price, Gross Margin 2015-2020 Table Sierra Sciences Llc Profile Table Sierra Sciences Llc Production, Value, Price, Gross Margin 2015-2020 Table Restorbio Profile Table Restorbio Production, Value, Price, Gross Margin 2015-2020 Table Insilico Medicine Profile Table Insilico Medicine Production, Value, Price, Gross Margin 2015-2020 Table Oisin Biotechnology Profile Table Oisin Biotechnology Production, Value, Price, Gross Margin 2015-2020 Table Senolytic Therapeutics Profile Table Senolytic Therapeutics Production, Value, Price, Gross Margin 2015-2020 Table Proteostasis Therapeutics Inc. Profile Table Proteostasis Therapeutics Inc. Production, Value, Price, Gross Margin 2015-2020 Table Prana Biotechnology Ltd. Profile Table Prana Biotechnology Ltd. Production, Value, Price, Gross Margin 2015-2020 Table Cleara Biotech Profile Table Cleara Biotech Production, Value, Price, Gross Margin 2015-2020 Figure Global Longevity and Anti-senescence Therapy Sales and Growth Rate (2015-2020) Figure Global Longevity and Anti-senescence Therapy Revenue ($) and Growth (2015-2020) Table Global Longevity and Anti-senescence Therapy Sales by Regions (2015-2020) Table Global Longevity and Anti-senescence Therapy Sales Market Share by Regions (2015-2020) Table Global Longevity and Anti-senescence Therapy Revenue ($) by Regions (2015-2020) Table Global Longevity and Anti-senescence Therapy Revenue Market Share by Regions (2015-2020) Table Global Longevity and Anti-senescence Therapy Revenue Market Share by Regions in 2015 Table Global Longevity and Anti-senescence Therapy Revenue Market Share by Regions in 2019 Figure North America Longevity and Anti-senescence Therapy Sales and Growth Rate (2015-2020) Figure Europe Longevity and Anti-senescence Therapy Sales and Growth Rate (2015-2020) Figure Asia-Pacific Longevity and Anti-senescence Therapy Sales and Growth Rate (2015-2020) Figure Middle East and Africa Longevity and Anti-senescence Therapy Sales and Growth Rate (2015-2020) Figure South America Longevity and Anti-senescence Therapy Sales and Growth Rate (2015-2020) Figure North America Longevity and Anti-senescence Therapy Revenue ($) and Growth (2015-2020) Table North America Longevity and Anti-senescence Therapy Sales by Countries (2015-2020) Table North America Longevity and Anti-senescence Therapy Sales Market Share by Countries (2015-2020) Figure North America Longevity and Anti-senescence Therapy Sales Market Share by Countries in 2015 Figure North America Longevity and Anti-senescence Therapy Sales Market Share by Countries in 2019 Table North America Longevity and Anti-senescence Therapy Revenue ($) by Countries (2015-2020) Table North America Longevity and Anti-senescence Therapy Revenue Market Share by Countries (2015-2020) Figure North America Longevity and Anti-senescence Therapy Revenue Market Share by Countries in 2015 Figure North America Longevity and Anti-senescence Therapy Revenue Market Share by Countries in 2019 Figure United States Longevity and Anti-senescence Therapy Sales and Growth Rate (2015-2020) Figure Canada Longevity and Anti-senescence Therapy Sales and Growth Rate (2015-2020) Figure Mexico Longevity and Anti-senescence Therapy Sales and Growth (2015-2020) Figure Europe Longevity and Anti-senescence Therapy Revenue ($) Growth (2015-2020) Table Europe Longevity and Anti-senescence Therapy Sales by Countries (2015-2020) Table Europe Longevity and Anti-senescence Therapy Sales Market Share by Countries (2015-2020) Figure Europe Longevity and Anti-senescence Therapy Sales Market Share by Countries in 2015 Figure Europe Longevity and Anti-senescence Therapy Sales Market Share by Countries in 2019 Table Europe Longevity and Anti-senescence Therapy Revenue ($) by Countries (2015-2020) Table Europe Longevity and Anti-senescence Therapy Revenue Market Share by Countries (2015-2020) Figure Europe Longevity and Anti-senescence Therapy Revenue Market Share by Countries in 2015 Figure Europe Longevity and Anti-senescence Therapy Revenue Market Share by Countries in 2019 Figure Germany Longevity and Anti-senescence Therapy Sales and Growth Rate (2015-2020) Figure UK Longevity and Anti-senescence Therapy Sales and Growth Rate (2015-2020) Figure France Longevity and Anti-senescence Therapy Sales and Growth Rate (2015-2020) Figure Italy Longevity and Anti-senescence Therapy Sales and Growth Rate (2015-2020) Figure Spain Longevity and Anti-senescence Therapy Sales and Growth Rate (2015-2020) Figure Russia Longevity and Anti-senescence Therapy Sales and Growth Rate (2015-2020) Figure Asia-Pacific Longevity and Anti-senescence Therapy Revenue ($) and Growth (2015-2020) Table Asia-Pacific Longevity and Anti-senescence Therapy Sales by Countries (2015-2020) Table Asia-Pacific Longevity and Anti-senescence Therapy Sales Market Share by Countries (2015-2020) Figure Asia-Pacific Longevity and Anti-senescence Therapy Sales Market Share by Countries in 2015 Figure Asia-Pacific Longevity and Anti-senescence Therapy Sales Market Share by Countries in 2019 Table Asia-Pacific Longevity and Anti-senescence Therapy Revenue ($) by Countries (2015-2020) Table Asia-Pacific Longevity and Anti-senescence Therapy Revenue Market Share by Countries (2015-2020) Figure Asia-Pacific Longevity and Anti-senescence Therapy Revenue Market Share by Countries in 2015 Figure Asia-Pacific Longevity and Anti-senescence Therapy Revenue Market Share by Countries in 2019 Figure China Longevity and Anti-senescence Therapy Sales and Growth Rate (2015-2020) Figure Japan Longevity and Anti-senescence Therapy Sales and Growth Rate (2015-2020) Figure South Korea Longevity and Anti-senescence Therapy Sales and Growth Rate (2015-2020) Figure Australia Longevity and Anti-senescence Therapy Sales and Growth Rate (2015-2020) Figure India Longevity and Anti-senescence Therapy Sales and Growth Rate (2015-2020) Figure Southeast Asia Longevity and Anti-senescence Therapy Sales and Growth Rate (2015-2020) Figure Middle East and Africa Longevity and Anti-senescence Therapy Revenue ($) and Growth (2015-2020) continued

About HongChun Research: HongChun Research main aim is to assist our clients in order to give a detailed perspective on the current market trends and build long-lasting connections with our clientele. Our studies are designed to provide solid quantitative facts combined with strategic industrial insights that are acquired from proprietary sources and an in-house model.

Contact Details: Jennifer GrayManager Global Sales+ 852 8170 0792[emailprotected]

NOTE: Our report does take into account the impact of coronavirus pandemic and dedicates qualitative as well as quantitative sections of information within the report that emphasizes the impact of COVID-19.

As this pandemic is ongoing and leading to dynamic shifts in stocks and businesses worldwide, we take into account the current condition and forecast the market data taking into consideration the micro and macroeconomic factors that will be affected by the pandemic.

https://neighborwebsj.com/

Read the original:
Global Longevity and Anti-senescence Therapy Market Report 2020 by Key Players, Types, Applications, Countries, Market Size, Forecast to 2026 (Based...

I replied, Well, they showed that individuals who received the active vaccine injection were much less likely to get the infection than those who got a placebo or dummy injection without active vaccine.

She listened intently with a slightly worried expression.

But to make the study completely objective, it was double-blind, I said.

Whats that? she asked.

Double-blind means that both sides are blind or not given information about who got the real vaccine or placebo, I replied. Not the clinical team with the doctor, nurse, and other research staff on one side, and the patient and family and friends on the other side. No one directly involved with the patient in the study is allowed to know.

Her reaction was spontaneous and swift: But thats against human nature! How can we prevented from knowing if we are getting the real vaccine?

As a researcher, I have conducted many clinical trials with patients who express concern about the possibility of receiving a placebo, or find it hard to comprehend the restrictive rules of a double-blind design. These are counterintuitive methods, though required by the US Food and Drug Administration (FDA), the European Medicines Agency (EMA), and other agencies worldwide. They are intended to increase objectivity because there is ample evidence that a positive bias naturally occurs in most patients and clinicians involved in a study.They expect the vaccine to be safe and effective, and their expectation often has a healing power of its own.

A long history confirms the need for research objectivity. Until the 18th century, average human longevity ranged from 30 to 50 years; it barely budged despite the thousands of new therapies pursued across the world, some based on ancient texts from a variety of cultures. But scientific proof was gradually replacing beliefs. Revolutionary advances like the discovery of antibiotics in the mid-20th century transformed human survival. Experimental methods to improve the accuracy of research findings, including the objective methods used routinely nowadays in clinical studies, were codified by scientists in the 20th century. During the last 2 centuries, the average human lifespan nearly doubledto over 75 years. The FDA adopted scientific methods by requiring that research studies in humans be conducted in phases. Phase 1 involves small-scale studies to determine safety, and at different doses, phase 2 involves mid-sized, double-blind studies with a placebo group to obtain initial information on efficacy and safety of the optimal doses identified in phase 1, and phase 3 requires large-scale, double-blind clinical trials with placebo built upon results from phases 1 and 2. If phase 3 results are positive, with sufficient safety and efficacy, the vaccine or drug is approved. But the work is not done. Phase 4 then begins with post-approval monitoring of side and adverse effects in those receiving the approved treatment or vaccine in standard clinical care.

Why are there so many hurdles to cross before approval, and more afterwards? Less than 1 in every 100 potential treatments makes it all the way from the basic science laboratory through clinical trials and finally regulatory approval for patient care. In other words, if we did not have the current regulatory system, tens of thousands of new vaccines, drugs and medical devices would be used widely, despite over 99% of them not meeting necessary standards of safety and efficacy. That would be like throwing us back to the healthcare standards of medieval and even earlier times.

My experience during the early days of the COVID-19 pandemic highlights the struggle to balance scientific knowledge with private beliefs and intrinsic daily habits. In late February 2020, I acquired N-95 masks and face-shields from our hospitals central supply and instructed all my clinical research staff to wear the mask and face-shield when seeing patients. In March 2020, just before the lockdown, we saw our last outpatient, who subsequently was hospitalized a few days later with COVID-19. I did not become ill but a few of my research staff members did, fortunately only with moderate symptoms that resolved in several weeks. Judging by when they became ill, they probably got the infection from that patient. When I asked, they told me that they had not worn the mask and face-shield continuously, as I had instructed. These team members routinely follow my instructions in carrying out their daily work but wearing a mask and face-shield went against their usual habits and beliefs.

If this was happening in a healthcare setting, the problems that we have seen with the publics response to the pandemic should not come as a surprise. To ensure a robust pandemic response in 2021, we all will need to better understand why so many people do not act in their own interest, and that of others. Public education about the science and the studies that produced FDA approval is essential, as is modeling by trustworthy, influential and diverse people doing the right thing.

But will that be enough? What do we need to know about those individuals (and groups) who demonstrate vaccine hesitancy, as has been abundant in refusals of flu and even measles vaccinations? The beliefs that underlie vaccine hesitancy may seem counter-intuitive, but they are prevalent and constitute a danger to that individuals health and to that of others. These actions may seem to go against the self-protective and social compact in human nature, except that it is other aspects of human nature, instinctive fear of the new and unknown as well as entrenched beliefs and habits, that are driving them. Let us hope it does not take centuries to understand what is going on and what works to alter vaccine hesitancy. We do not have the time for that.

Dr Devanand is professor of Psychiatry and Neurology and Director of Geriatric Psychiatry, Columbia University Irving Medical Center.

Read more here:
Vaccines at the Dinner Table - Psychiatric Times

Go up a gear with jogs and bike rides

When you feel fitter, make some of this daily activity a more moderate intensity, such as a spin on an indoor bike, some fast-paced walking or a light jog. Moderate-level cardio should be done three days a week, says Roberts. The level should feel like a seven out of 10 intensity. You should be able to have a conversation but should also be raising a sweat.

This helps fortify the heart and control your blood pressure and blood glucose levels. We need to be more active than we think, says Roberts.

To really fine-tune your heart and lungs, and trigger cellular regeneration as you age, you need high-intensity exercise, too. We are designed to be challenged and we adapt fast, says Roberts. If we are not pushed, cellular redevelopment starts to slow.

Roberts recommends two to three high-intensity sessions per week. For those getting back into shape, a body weight circuit, or sprints on an indoor bike or rowing machine, are all good options. But if you are feeling fitter, try some sprint intervals outdoors, or a sweaty home cardio circuit with med ball throws and kettlebell swings.

Muscle mass and bone health decline with age, making you vulnerable to injuries and impairments, but there is a way to fight back. Weight training helps retain muscle mass and supports nerve function and bone density, explains Roberts. By increasing the resistance pressure, or the overload, we also increase our central nervous stimulation response which helps with our hormone production levels. This in turn helps to regenerate tissue cells, muscles, tendons, ligaments, hair and skin.

Roberts suggests doing resistance training twice a week. Start with simple exercises, such as squats, lunges and press-ups, for three to sixweeks, then build up to heavier weights, with 6-8 reps per lift. If you dont have dumbbells at home, you can try the smart body weight techniques Roberts is now using on Zoom workouts with his clients. The key is to keep it varied, he explains. You can build in pauses, holds, different ranges of motion and different speeds to work your muscle fibres. With a simple squat, for example, you might hold the position midway through, so you're building tension in the quads and inner thighs. This is called a static contraction and is used in rehab to create strength quickly. Just using a chair to do a step up, and changing the speed of that step up, by moving up slowly for 2 seconds, and down slowly for 3 seconds, is another good example.

Sitting on an indoor bike will build your fitness, yes, but playing a racket sport or team sport when were allowed to will also protect your grey matter. Find sports that encourage you to think, advises Roberts. Tennis is very analytical. Youre always working out a strategy, which is good for your synapses and your nerve endings. When you have to react quickly, it involves a vast amount of electronic responses in your brain, which is anti-ageing.

A strong core will protect your posture and flexibility as you age. As we get older, we get more joint issues and back pain which stops us doing things and leads to inactivity, explains Roberts. Thats why he suggests doing 10-15 minutes of mobility and activation exercises before each workout. Planks, V-sits and glute bridges work well, but yoga poses like the downward dog or child pose are also good for mobility.

This kind of supplementary work can also help to prevent more serious injuries as you age. If you lose your stability in your back, shoulders and hips, your chances of falling go up enormously, says Roberts. Even if you hurt your ankle or knee, your level of activity gets reduced and thats when people gain weight. So keep up a good mobility programme, whether it is through Pilates or foam roller work, so you keep feeling agile and young.

The moment we stop moving properly, the older we feel.

Read more:Matt Roberts: My body fat and fitness levels are the same at 46 as they were at 20

Read more:A health test said my biological age is 41, but Im only 30

Read more:
Matt Roberts: the exercise regime that will help you stay younger for longer - Telegraph.co.uk

MOUNTAIN VIEW, Calif., Jan. 12, 2021 /PRNewswire/ --Turn Biotechnologies, a company developing medicines for currently untreatable age-related conditions, announced that it has acquired the global rights for new technology that reprograms cells to undo many of the effects of aging.

The company licensed its epigenetic reprogramming of age (ERA) technology from Stanford University, where it was developed by three researchers who founded Turn. It is the first technology to maintain cellular identity while restoring specific cells' youthful functionality, to trigger the body's ability to fight age-related diseases.

The company announced that it has also filed for patents to protect its technology in major-market nations on six continents.

"ERA technology is an extremely powerful platform and can be used to treat a variety of diseases throughout the body," said Anja Krammer, Turn CEO. "The steps we have taken ensure that the fruits of our research can benefit millions of people around the world."

A study published last March in the journal "Nature Communications" highlighted the promise of Turn's ERA technology to treat age-related health conditions. The study found that old human cells can be induced into a more youthful and vigorous state when they are exposed to a rejuvenating treatment that triggers the limited expression of a group of proteins known as Yamanaka or transcription factors, which are important to embryonic development.

ERA uses messenger RNA (mRNA) to deliver these transcription factors to the cells' epigenome, which controls cellular activity. As the epigenome ages, it prevents a cell from functioning optimally. The transcription factors which can be delivered in a variety of combinations to target different cells effectively revitalize the epigenome, restoring the cells' ability to behave more youthfully.

"The ability to precisely control a cell's rejuvenation means we will be able to turn back the clock on cellular vitality, effectively restoring cells' ability to heal or regenerate damaged tissue," said Jay Sarkar, Turn's chief technology officer and a company founder who helped to develop the ERA technology. "Our research offers promise to people suffering from age-related diseases for which there are currently no cures."

Turn's technology uses mRNA to produce instructions that induce cells to treat or prevent disease. Messenger RNA made possible the speedy development of two recently announced COVID-19 vaccines. An advantage of mRNA is that it is safe because it never enters the cell nucleus where DNA is kept and the cell effectively gets rid of the mRNA after it has used the instructions carried by it.

Just as it led to the lightning-fast development of COVID-19 vaccines, use of mRNA promises to revolutionize the development of therapeutics by making that development safer, faster, more efficient and extremely tunable to patient need.

Turn is currently completing pre-clinical research on tailored therapies targeting indications in dermatology, osteo-arthritis and cartilage damage, ophthalmology and musculature.

ABOUT TURN BIOTECHNOLOGIES

Turn is a pre-clinical-stage company focused on repairing tissue at the cellular level. Our proprietary mRNA technology combats the effects of aging in the epigenome, thus restoring optimal gene expression and enabling cells to function as vigorously as when they were younger. Our technology provides a platform from which to attack a variety of diseases related to age. The company has the financial backing of Methuselah Fund, which focuses its investments to extend the healthy human lifespan; Formic Ventures, which invests in biotech start-ups focused on human longevity; and Shanda Group, a private global investment firm. For more information, see http://www.turn.bio.

FOR MORE INFORMATION, CONTACT:Jim Martinez, rightstorygroup[emailprotected] or (312) 543-9026

SOURCE Turn Biotechnologies

View post:
Turn Biotechnologies Licenses Revolutionary Technology to Unwind the Effects of Aging at a Cellular Level - PRNewswire